XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
   Non-Hodgkin's Lymphoma
   Multiple Myeloma
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Blood Channel
subscribe to Blood newsletter

Latest Research : Cancer : Blood

   DISCUSS   |   EMAIL   |   PRINT
Genes linked to treatment resistance in leukemia
Jun 4, 2005, 02:07, Reviewed by: Dr.


"This research showcases a new direction for cancer treatment � personalized chemotherapy based on the genetics of the patient. In our study, several common genetic variations were found to predict the outcomes of leukemia patients, demonstrating that genotyping may become an important tool for tailoring treatment and improving an individual's chance of a cure."


 
Today, the most common childhood cancer is cured in about 80 percent of patients; only forty years ago, this number was closer to five percent. In efforts to further increase the survival rate, researchers from St. Jude Children's Research Hospital, the University of Tennessee, and the University of Chicago studied how an individual's genetics might play a role in the effectiveness of chemotherapy drugs. Their findings will be published in the June 15, 2005, issue of Blood, the official journal of the American Society of Hematology.

The researchers studied 246 children with acute lymphoblastic leukemia (ALL), all of whom were assigned to one of two groups that determined the intensity of therapy. Patients with poorer prognostic factors � 130 children � were assigned to a high-risk group; the remaining children were enrolled in the lower-risk arm.

In a process known as genotyping, DNA was extracted from the normal blood cells of each child and screened for sixteen common genetic variations. The studied genes code for enzymes which are involved in the metabolism and activity of chemotherapy drugs in the body, and were therefore likely to have effects on treatment outcomes.

In the analysis of the high-risk group, the GSTM1 non-null genotype was associated with hematological relapse, a recurrence of the cancer in the blood and bone marrow and the most common reason for treatment failure in childhood ALL. This risk was further increased if the child also had a TYMS 3/3 genotype. No genotype was associated with hematological relapse among patients in the lower-risk arm of the study.

The researchers also looked for evidence of leukemia in each patient's central nervous system (CNS), a region that is vulnerable to infiltration by cancer cells. Genetic variations may have particular impact on how drugs penetrate the "blood-brain" barrier that protects the CNS. For patients in the high-risk arm, the VDR FokI genotype was found to be prognostic for CNS relapse, especially when combined with a VDR intron 8 genotype. In the low-risk group, the TYMS 3/3 genotype was a risk factor.

For children with these unfavorable genotypes, a potential solution may be using drugs that are not affected by these particular enzymes or increasing the dosage of drugs that are. And, in the future, a simple blood test may be all that's needed to make that determination.

"This research showcases a new direction for cancer treatment � personalized chemotherapy based on the genetics of the patient," said Mary Relling, Pharm.D., St. Jude faculty member and lead study author. "In our study, several common genetic variations were found to predict the outcomes of leukemia patients, demonstrating that genotyping may become an important tool for tailoring treatment and improving an individual's chance of a cure."
 

- American Society of Hematology
 

www.hematology.org

 
Subscribe to Blood Newsletter
E-mail Address:

 

This work was supported by grants from the National Cancer Institute and the NIH/NIGMS Pharmacogenetics Research Network and Database; by a Center of Excellence grant from the State of Tennessee; and by American Lebanese Syrian Associated Charities (ALSAC).

The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematology, is the most cited peer-reviewed publication in the field. Blood is issued to Society members and other subscribers twice per month, available in print and online at www.bloodjournal.org.


Related Blood News

Medication errors affect children's leukemia treatment
JAK-STAT pathway inhibitors are likely to be effective against some leukemias
HO-1 in sickle cell disease
Dasatinib treats resistant cases of CML
HBZ protein enhance ability of HTLV-1 to establish persistent infection
Gene expression signature for Burkitt lymphoma identified
Bcr-Abl mutation and the loss of Arf genes triggers an aggressive form of ALL
New simple and inexpensive test for follow-up of acute lymphoblastic leukemia (ALL)
miRNAs abnormal signalling may lead to platelet-related leukemias
DNA itself can act as a mutagen


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us